CARIS LIFE SCIENCES, INC. (CAI) EBITDA
- 2026-06-30: Basis Reported; EBITDA $33.43M; Operating income (m); Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA $10.35M; Operating income (m); Depreciation and amortization (m).
- 2025-12-31: Basis Reported; EBITDA $92.7M; Operating income (m); Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA $37.54M; Operating income (m); Depreciation and amortization (m).
Complete source-backed ebitda history.
- Available history
- 2023-12-31 to 2026-06-30
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | $33.43M | (m) | (m) | (m) | 12.68% | (m) | $28.48M* | (m) | $32.36M | (m) | $23.00K |
|---|
| 2026-03-31 | Reported | $10.35M | (m) | (m) | (m) | 4.79% | $10.34M | $32.88M | (m) | $31.32M | (m) | -$134.00K |
|---|
| 2025-12-31 | Reported | $92.7M | (m) | (m) | (m) | 31.65% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2025-09-30 | Reported | $37.54M | (m) | (m) | (m) | 17.31% | $7.09M* | $62.42M* | (m) | $21.62M | (m) | $0.00 |
|---|
| 2025-06-30 | Reported | -$11.59M | (m) | (m) | (m) | -6.39% | $1.39M* | $7.29M* | (m) | $25.05M | (m) | $0.00 |
|---|
| 2025-03-31 | Reported | -$50.91M | (m) | (m) | (m) | -42.10% | $2.69M | -$31.34M | (m) | $23.07M | (m) | $0.00 |
|---|
| 2024-12-31 | Reported | -$27.98M | (m) | (m) | (m) | -21.54% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2024-09-30 | Reported | -$50.34M | (m) | (m) | (m) | -49.54% | $1.83M* | -$69.43M* | (m) | $27.64M | (m) | $0.00 |
|---|
| 2024-06-30 | Reported | -$55.41M | (m) | (m) | (m) | -55.38% | (m) | (m) | (m) | $24.79M | (m) | $0.00 |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | $67.73M | (m) | (m) | (m) | 8.34% | $16.26M | $83.16M | (m) | $101.58M | (m) | $0.00 |
|---|
| 2024-12-31 | Reported | -$208.21M | (m) | (m) | (m) | -50.50% | $8.44M | -$245.20M | (m) | $113.92M | (m) | $0.00 |
|---|
| 2023-12-31 | Reported | -$270.55M | (m) | (m) | (m) | -88.38% | $22.32M | -$276.10M | (m) | $116.88M | (m) | $0.00 |
|---|